StockData
OmniAb, Inc. logo

OmniAb, Inc. (OABI) company profile

OABINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABIW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 9/3036% above fair value
$5.05+0.16 (+3.27%)

Close on Nov 17, 2026Market cap $736.60MP/E –Yield –

About OmniAb

Services-Commercial Physical & Biological Research, SIC 8731

OmniAb, Inc. creates and licenses antibody discovery technologies to pharmaceutical and biotechnology companies and academic research institutions. Its platform incorporates genetically engineered transgenic animals—including rats, mice, chickens, and cow-inspired models—to produce diverse, naturally optimized antibody repertoires with human genetic sequences. These proprietary animals are complemented by computational antigen design, microfluidic and microcapillary single B cell screening platforms, and artificial intelligence-driven bioinformatics suites for data analysis and hit optimization. Together, these technologies support the discovery of diverse therapeutic modalities such as monoclonal and bispecific antibodies, single-domain antibodies, and antibody-drug conjugates.

As of December 31, 2025, the company collaborated with 107 active partners supporting 407 active programs across diverse geographic regions and therapeutic areas. These partnered programs included 27 antibodies in active clinical development, two candidates under regulatory review, and three commercialized products. The provided text contains no statements regarding the company's founding year, website address, or headquarters location.

Summary of the business section of OmniAb's latest annual report, written by StockData.

Company profile

Company

Legal name
OmniAb, Inc.
Headquarters
Emeryville, CA
Address
5980 Horton Street, Suite 600 94608
Phone
(510) 250-7800
Website
omniab.com
Employees
107, Dec 31, 2025
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
OABI
Other tickers
OABIW
Former tickers
AHPA until Nov 7, 2022
Exchange
Nasdaq
IPO date
Aug 11, 2021
Shares outstanding
146M, Oct 23, 2026
Public float
$144.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1846253
CUSIP
68218J301
ISIN
US68218J3014
FIGI
BBG011J3QM39
Share class FIGI
BBG011J3QM48
LEI
5493008K7TB0IKP37H79
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Matthew W. FoehrPresident and CEO, Director4,439,736
Amechi Ekeke NwachukuChief Operating Officer–
Charles S. BerkmanChief Legal Officer399,085
Kurt A. GustafsonExecutive VP, Finance and CFO261,483
Steven LoveDirector105,000
Steven C. CrouseDirector33,333
Carolyn R. BertozziDirector113,308
Jennifer R. CochranDirector185,274
Philip J. GotwalsDirector33,333
John L. HigginsDirector2,962,320

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Matthew W. Foehr
Chief Executive Officer and Director
$620.87K$640.50K$2.10M$436.29K$9.47K$3.81M+5%
Kurt A. Gustafson
Chief Financial Officer
$496.78K$205.88K$676.49K$224.41K$9.55K$1.61M-4%
Charles S. Berkman
Chief Legal Officer and Secretary
$503.53K$205.88K$676.49K$227.46K$11.08K$1.62M-4%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Aug 11, 2021
Offer price
$10.00
Securities offered
20,000,000
Gross proceeds
$200.00M
Exchange
Nasdaq
First trading day
Sep 30, 2021
First-day close
$9.76-2.4%
Lock-up ends (est.)
Mar 29, 2022

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 107 active partners with 407 active programs using the OmniAb technology platform, including 27 OmniAb-derived antibodies in clinical development by our partners, two under regulatory review, and three approved products developed and commercialized by our partners.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?